efit. The main difference was in terms of harms, and they were relatively modest.
A challenge for the Roundtable, a member said, is that genome-based health is such a diffuse and enormous field with broad stakeholder representation. He asked the panel what they thought should be priorities for translating genomics into health care for the next 5 years. What is the best investment of intellectual and tangible resources?
Berg said family physicians in primary care take all comers, and never know what will be behind the door. Having tests or innovations that can be applied in that setting is no different for a genetic test than for anything else. Many factors compete for the attention of clinicians right now. Although most would agree that it would be great to find opportunities to use genetic tests, so far in his practice, Berg did not know of anyone using a genetic test for a common clinical condition. To be a viable business model, the tests need to be applicable to common clinical scenarios. Like any other innovation, it would need to be fast enough and cheap enough, and have demonstrated improvement in clinical outcomes in order to be adopted into practice.
Phillips said the Roundtable has a unique opportunity to bring the many different perspectives together, and to look across issues in an objective way. More generally, personalizing medicine will continue to be of interest, whether through genetics, family history, or various other means. There is a push toward comparative effectiveness and toward maintaining quality while reducing cost. The Roundtable’s priorities should be developed within that context of where the health care system is going overall.